Imagen de perfil
Stagnating share price since 2y+ tho
1
Imagen de perfil
@Jo_Wolf 15-20% dividend cagr. It's a marathon. Nothing like Pfizer or Altria. Altria was the opposite purchase: high yield, low cagr.
Imagen de perfil
@Noord26 I see they are doing buybacks, net income is growing, debt repaid is higher than debt issued. It's a small yield but the payout ratio isn't high and the growth is good.

Seem the only bad thing is this stagnating price...
On my watch list then 😉

Thanks for the tips !
1